Terms: = Prostate cancer AND ERCC4, XPF, 2072, ENSG00000175595, Q92889 AND Treatment
3 results:
1. Association of treatment Modality, Functional Outcomes, and Baseline Characteristics With treatment-Related Regret Among Men With Localized prostate cancer.
Wallis CJD; Zhao Z; Huang LC; Penson DF; Koyama T; Kaplan SH; Greenfield S; Luckenbaugh AN; Klaassen Z; Conwill R; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Hoffman KE; Barocas DA
JAMA Oncol; 2022 Jan; 8(1):50-59. PubMed ID: 34792527
[TBL] [Abstract] [Full Text] [Related]
2. Variation in adjuvant and early salvage radiotherapy after robot-assisted radical prostatectomy for prostate cancer: a population-based cohort study.
Draulans C; Van Damme N; Isebaert S; Everaerts W; Silversmit G; Joniau S; De Meerleer G; Van Eycken E; Haustermans K;
Acta Oncol; 2020 Aug; 59(8):904-910. PubMed ID: 32723224
[No Abstract] [Full Text] [Related]
3. Factors predicting efficacy and adverse effects of enzalutamide in Japanese patients with castration-resistant prostate cancer: results of retrospective multi-institutional study.
Terada N; Akamatsu S; Okada Y; Negoro H; Kobayashi T; Yamasaki T; Matsui Y; Inoue T; Kamba T; Ogawa O
Int J Clin Oncol; 2016 Dec; 21(6):1155-1161. PubMed ID: 27351872
[TBL] [Abstract] [Full Text] [Related]
